Zepbound Alternative 2026: Compounded Tirzepatide at $125/Month

Zepbound vs Mounjaro: Why There Are Two Tirzepatide Products

Eli Lilly has two FDA-approved tirzepatide products: Mounjaro (for type 2 diabetes, approved 2022) and Zepbound (for chronic weight management, approved 2023). The active molecule is identical: tirzepatide at doses up to 15mg per week. The difference is the FDA indication, which determines how the drug is labeled, marketed, and, crucially, how insurance covers it.

An FDA approval specifically for obesity allows Eli Lilly to market Zepbound to patients and providers for weight management without the type 2 diabetes indication. It also allows plans with specific obesity medication benefits to cover Zepbound under those benefits. But since most insurance plans and all Medicare plans currently exclude obesity medication coverage, this distinction matters less in practice than it should.

For patients accessing tirzepatide through Trimi's compounded program, the Mounjaro/Zepbound labeling distinction does not apply. Your Trimi provider prescribes compounded tirzepatide for weight management at the clinically appropriate dose, and the compounding pharmacy prepares it at your prescribed concentration. Compounded tirzepatide is not one of Eli Lilly's FDA-approved products: it is prepared per individual prescription by a state-licensed 503A pharmacy and has not been evaluated by the FDA for safety or effectiveness.

The Science: Why Tirzepatide Works So Well

Tirzepatide's effectiveness stems from its novel dual mechanism. Prior GLP-1 medications like semaglutide activate only GLP-1 receptors. Tirzepatide simultaneously activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, a combination that appears to produce synergistic effects on appetite suppression, energy expenditure, and fat metabolism.

In the SURMOUNT-1 trial, the pivotal phase 3 study for tirzepatide in obesity, participants at the 15mg dose achieved average weight loss of 22.5% of body weight over 72 weeks, approximately 52 pounds for a 230-pound person. At the 5mg and 10mg doses, average weight loss was 15% and 19.5% respectively. These results are substantially greater than any previously approved weight loss medication.

In SURMOUNT-5, a head-to-head comparison of tirzepatide versus semaglutide 2.4mg for obesity, tirzepatide produced approximately 47% greater absolute weight loss. Patients on tirzepatide lost an average of 20.2% of body weight versus 13.7% for semaglutide. Both medications are clinically effective; tirzepatide is simply more effective.

Those results come from trials of the FDA-approved product. Trimi's compounded tirzepatide is priced at $125 per month and is not FDA-approved as a drug. For the full pricing comparison across all major GLP-1 telehealth providers, see our cheapest legal GLP-1 online cornerstone; for the comparison between tirzepatide and semaglutide, see our semaglutide vs tirzepatide guide.

Compounding Regulations: How Trimi Ensures Quality

Compounded tirzepatide is prepared under the same federal regulations that govern all compounded medications in the United States. Trimi's partner pharmacies operate under the most stringent category of compounding oversight:

• 503A State-Licensed Pharmacy Licensure

  503A pharmacies compound per individual patient prescription under state board of pharmacy licensure and USP sterile-compounding standards. They are not FDA-registered outsourcing facilities, and their preparations are not FDA-approved drugs.

• PCAB Accreditation

  Pharmacy Compounding Accreditation Board accreditation requires pharmacies to meet rigorous quality standards beyond basic state licensing requirements.

• Third-Party Batch Testing

  Every batch of compounded tirzepatide is tested by an independent laboratory for potency (correct active ingredient concentration), purity (absence of contaminants), and sterility (absence of microbial contamination).

• Cold Chain Handling

  Tirzepatide is a peptide that requires temperature-controlled storage and shipping. Trimi's pharmacy partners handle cold chain packaging to ensure medication arrives in stable condition.

• USP 797 Compliance

  Sterile compounding standards set by the United States Pharmacopeia govern the preparation environment, testing requirements, and beyond-use dating for all sterile preparations.

For a comprehensive guide to evaluating compounding pharmacy quality, see our compounded GLP-1 quality guide. For the full economic explanation of why compounding makes $125 tirzepatide possible, see why compounded GLP-1s are so affordable.

Who Is Eligible for Compounded Tirzepatide?

Compounded tirzepatide through Trimi is available to adults who meet standard clinical criteria for GLP-1 weight loss therapy. Your Trimi provider evaluates:

Your Trimi provider reviews your specific medical history during the consultation. If you have questions about whether you qualify before starting the assessment, our GLP-1 candidate guide covers eligibility criteria in detail.

Managing the Transition from Zepbound to Compounded Tirzepatide

If you are currently on Zepbound and switching to compounded tirzepatide for cost reasons, tell your new provider your current dose and how long you have been on it. Your provider decides where to pick up your titration.

The main practical difference is the injection delivery system. Zepbound uses an auto-injector pen that conceals the needle. Compounded tirzepatide uses a standard vial and syringe. For patients making the switch, Trimi provides detailed injection technique instructions, and your provider is available for questions during the adjustment period.

Time the switch so your first compounded dose aligns with your next scheduled Zepbound injection. Tell your Trimi provider your current dose (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, or 15mg) and how long you have been at that dose. They will match your prescription accordingly.